ClinicalTrials.gov
public full text
Public Domain
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses. Each participant can receive up to 3 doses, with a minimum 7 day washout between dosing periods. Side effects will be documented. This study is approximately 9 weeks long, not including screening. Screening is required within 6 weeks prior to the start of the study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes#862442
- A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus#868322
- A Study of LY3410738 in Healthy Adult Participants#1137973
- A Study of LY4302814 in Healthy Participants#1058487
- A Study of LY3323795 in Healthy Participants#980820
Record · ID 871541
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive